PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazilian Private Payer Perspective

✍ Scribed by Caponero, R.; Santos, E.A.V.; Buschinelli, C.T.; Ferracini, M.; Ngoh, C.A.

• Book ID: 123122861
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 59 KB
• Volume: 14
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2011.08.1167